comparemela.com

Page 3 - Urogen Rtgel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials

In ATLAS, UGN-102 Demonstrated Superiority to TURBT with a 55% Reduction of Risk for Recurrence, Progression or Death in Patients who Received UGN-102 ENVISION Showed a Complete Response.

Liz barrettUrogen rtgelSandip prasadUrogen pharma ltdCompany investor relationsDrug administrationMorristown medical center atlantic health systemUrogen pharmaNew drug applicationChief executive officerGenitourinary surgical oncologyMorristown medicalAtlantic health systemInvestor relationsPrivate securities litigation reform actRisk factors

UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of James Robinson,.

Depaul universityUnited statesUrogen rtgelJames robinsonLiz barrettAmerica phBoard of directors urovant sciencesChicago chapter of the young presidents organizationExchange commissionBoard of directors the pharmaceutical researchUrovant sciencesClub of chicagoUrogen pharma ltdPhrma state committeePlough pharmaceuticalsUrogen pharma

UroGen Pharma to Host UGN-102 Data Event on July 27, 2023

Program to Highlight Topline Results from the Phase 3 ATLAS and Pivotal ENVISION Clinical Trials

Urogen rtgelUrogen pharma ltdCompany investor relationsUrogen pharmaKey opinion leadersInvestor relationsNew drug applicationPrivate securities litigation reform actRisk factorsQuarterly report

Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis. | June 20, 2023

United statesUrogen rtgelSanta monicaMark schoenbergUrogen pharmaJennifer linehanDrug administrationExchange commissionRoute of administrationJoseph cancer instituteProvidence specialty medical groupUrogen pharma ltdNephrostomy administrationSafety outcomesEuropean urology focusAssociate professor

UroGen Pharma - New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO in the Treatment of UTUC of the Ureter and Renal Pelvis

PRINCTON - UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a. | May 1, 2023

United statesMark schoenbergJoseph jacobUrogen rtgelBladder cancer programAmerican urological association meetingUrogen pharma ltdExchange commissionGen pharmaFirst analysisUreteral tumorsMedical universityChief medical officerPrivate securities litigation reform actRisk factorsStates securities

vimarsana © 2020. All Rights Reserved.